Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study. Lee CH, Lui DT, Mak LY, Fong CH, et al. Diabetes Obes Metab 2024 Nov 5. doi: 10.1111/dom.16049.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lee CH, Lui DT, Mak LY, Fong CH, et al. Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study. Diabetes Obes Metab 2024 Nov 5. doi: 10.1111/dom.16049.
PMID: 39497579